After Sputnik V vaccine success in Russia, it will be manufactured in India.

The success rate of sputnik is very profound, and one of the manufactures is India.

Russian vaccine Sputnik V is 91.6% effective compared to Covid-19, according to results published Tuesday that independent experts say reducing public exposure is a jab, Moscow has already begun. Experts say the results of the Phase III trial mean that the world had another effective weapon to fight the deadly epidemic and to some extent confirmed Moscow's decision to release the vaccine before the final details were released.

A new analysis of data from 20,000 Phase 3 trial participants, published in the medical journal The Lancet, suggests that the two-dose vaccine provides more than 90 percent efficacy compared to Covid-19 symptoms. On Tuesday, Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF), which oversees the export of the vaccine, said production had begun in India and South Korea, and would be launched in China this month. Dmitriev also added that the volumes were also produced by a manufacturer in Brazil.

Dr Reddy's has partnered with the Russian Direct Investment Fund (RDIF) to conduct tests for the treatment of Sputnik V vaccine and its distribution rights in India. Dr Reddy's Laboratories last month obtained approval from the Drugs Control General of India (DCGI) to prosecute a third phase of the Sputnik V vaccine clinic of COVID-19.